BridgeBio Pharma/$BBIO
1D1W1MYTD1Y5YMAX
Capital at risk
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
- Ticker
- $BBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,001
- Headquarters
- Palo Alto, United States
- Website
- bridgebio.com
BridgeBio Pharma Metrics
BasicAdvanced
$13B
-
-$3.57
0.98
-
Price and volume
Market cap
$13B
Beta
0.98
52-week high
$93.42
52-week low
$48.78
Average daily volume
2.1M
Financial strength
Current ratio
3.275
Quick ratio
1.094
Long term debt to equity
-1.346
Total debt to equity
-1.346
Interest coverage (TTM)
-2.32%
Profitability
EBITDA (TTM)
-472.752
Gross margin (TTM)
94.44%
Net profit margin (TTM)
-97.03%
Operating margin (TTM)
-67.01%
Effective tax rate (TTM)
0.24%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
-26.00%
Return on equity (TTM)
32.77%
Valuation
Price to revenue (TTM)
18.607
Price to book
-5.31
Price to tangible book (TTM)
-5.25
Price to free cash flow (TTM)
-30.307
Free cash flow yield (TTM)
-3.30%
Free cash flow per share (TTM)
-2.257
Growth
Revenue change (TTM)
202.39%
Earnings per share change (TTM)
-12.88%
3-year revenue growth (CAGR)
400.87%
3-year earnings per share growth (CAGR)
-1.69%
What the Analysts think about BridgeBio Pharma
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
Analyst projections of the future price of BridgeBio Pharma stock.
Bulls say / Bears say
Attruby is showing strong commercial momentum: second-quarter US net product revenue reached $222.4 million, while total revenue was $243.7 million. The company says growth is being led by treatment-naive patients, which supports a larger and more durable market opportunity. (BridgeBio Pharma, BioSpace)
BridgeBio has three late-stage products moving towards launch: BBP-418 and encaleret have received FDA Priority Review, while infigratinib produced positive Phase 3 results and has been submitted for approval. This gives investors several near-term regulatory catalysts beyond Attruby. (BridgeBio Pharma, BridgeBio Pharma)
The $1 billion preferred-equity financing completed in July lifted cash to about $1.7 billion. That gives BridgeBio more capacity to fund three planned launches and continue developing its pipeline without relying immediately on another conventional equity raise. (BridgeBio Pharma)
The business is still loss-making despite rapid revenue growth: second-quarter operating expenses were $335.7 million and the operating loss was $107.1 million. Profitability therefore depends on Attruby continuing to scale and the new launches arriving on schedule. (BridgeBio Pharma, SEC filing)
Attruby's clinical advantage over tafamidis is not yet proven by a direct head-to-head trial. Recent supportive evidence relies on indirect or real-world comparisons, while future generic tafamidis could create pricing and formulary pressure. (BioSpace, StockAnalysis)
The three pipeline launches remain approval-dependent rather than commercial assets: BBP-418 has a November 2026 FDA action date, encaleret has a May 2027 date, and infigratinib is still awaiting its FDA review timetable. Any regulatory delay or rejection would push back the expected revenue inflection. (BridgeBio Pharma, BridgeBio Pharma)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
BridgeBio Pharma Financial Performance
Revenues and expenses
BridgeBio Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
BridgeBio Pharma News
AllArticlesVideos
Funds containing BridgeBio Pharma
AllUSDGBPEUR
Fund name | Fund size | $BBIO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.95% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.95% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.16% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.16% |
iShares MSCI World Small Cap$WSML | $9B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.